Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Ibrutinib (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Interim results (n=6) released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.
- 06 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.